

Vivek Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10825990/publications.pdf>

Version: 2024-02-01

24
papers

667
citations

623188

14
h-index

642321

23
g-index

26
all docs

26
docs citations

26
times ranked

870
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D ₃ Dopamine Receptor. ACS Chemical Neuroscience, 2020, 11, 3309-3320.	1.7	13
2	Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D ₃ Receptor Antagonists and Partial Agonists. Journal of Medicinal Chemistry, 2019, 62, 9061-9077.	2.9	30
3	Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens. Molecular Neurobiology, 2019, 56, 6756-6769.	1.9	33
4	Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. Neuropsychopharmacology, 2019, 44, 1415-1424.	2.8	61
5	Novel and Potent Dopamine D ₂ Receptor Go-Protein Biased Agonists. ACS Pharmacology and Translational Science, 2019, 2, 52-65.	2.5	43
6	Photoaffinity-Mediated Identification of a Third Citalopram Analog Binding Site on the Serotonin Transporter. FASEB Journal, 2018, 32, 680.1.	0.2	1
7	Evidence for a Stereoselective Mechanism of Action for Non-competitive Antagonism of the D3 Dopamine Receptor by Extended-Length Bitopic Ligands. FASEB Journal, 2018, 32, 827.12.	0.2	0
8	Synthesis and Pharmacological Characterization of Novel <i>trans</i> -Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D ₃ Receptor (D ₃ R). Journal of Medicinal Chemistry, 2017, 60, 1478-1494.	2.9	44
9	Novel Bivalent Ligands Based on the Sumanriole Pharmacophore Reveal Dopamine D ₂ Receptor (D ₂ R) Biased Agonism. Journal of Medicinal Chemistry, 2017, 60, 2890-2907.	2.9	43
10	Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D ₃ Receptor. Journal of Medicinal Chemistry, 2017, 60, 580-593.	2.9	49
11	Nanopharmacological Force Sensing to Reveal Allosteric Coupling in Transporter Binding Sites. Angewandte Chemie, 2016, 128, 1751-1754.	1.6	3
12	Nanopharmacological Force Sensing to Reveal Allosteric Coupling in Transporter Binding Sites. Angewandte Chemie - International Edition, 2016, 55, 1719-1722.	7.2	29
13	Novel Analogues of (<i>R</i>)-5-(Methylamino)-5,6-dihydro-4 <i>H</i> -imidazo[4,5,1- <i>ij</i>]quinolin-2(1 <i>H</i>)-one (Sumanriole) Provide Clues to Dopamine D ₂ /D ₃ Receptor Agonist Selectivity. Journal of Medicinal Chemistry, 2016, 59, 2973-2988.	2.9	33
14	Highly Selective Dopamine D ₃ Receptor (D ₃ R) Antagonists and Partial Agonists Based on Eticlopride and the D ₃ R Crystal Structure: New Leads for Opioid Dependence Treatment. Journal of Medicinal Chemistry, 2016, 59, 7634-7650.	2.9	73
15	1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities. Archiv Der Pharmazie, 2015, 348, 837-860.	2.1	75
16	Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (<i>S</i>)-Citalopram. Journal of Medicinal Chemistry, 2015, 58, 5609-5619.	2.9	10
17	Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. European Neuropsychopharmacology, 2015, 25, 1448-1461.	0.3	20
18	Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66. ACS Medicinal Chemistry Letters, 2014, 5, 647-651.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Novel and High Affinity Fluorescent Ligands for the Serotonin Transporter Based on (<i>S</i>)-Citalopram. ACS Medicinal Chemistry Letters, 2014, 5, 696-699.	1.3	20
20	Anti-inflammatory activity of a naphthyridine derivative (7-chloro-6-fluoro-N-(2-hydroxy-3-oxo-1-phenyl-3-(phenylamino)propyl)-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide) possessing in vitro anticancer potential. International Immunopharmacology, 2013, 15, 606-613.	1.7	3
21	Photochemistry of <i>o</i>-Fluoranil. Journal of Organic Chemistry, 2012, 77, 5017-5021.	1.7	11
22	The Multifaceted Reactivity of <i>o</i>-Fluoranil. Journal of Organic Chemistry, 2012, 77, 966-970.	1.7	11
23	1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity. European Journal of Medicinal Chemistry, 2009, 44, 3356-3362.	2.6	37
24	Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1169-1178.	2.5	9